Moscow, Oct 17 (UNI) Russian Direct Investment Fund (RDIF) and Dr Reddy said on Saturday that he had received a green light from the Drugs Controller General of India (DCGI) to conduct Phase 2 and 3 trial of Russia's COVID-19 vaccine, Sputnik V.
The RDIF and Dr Reddy’s entered into a partnership to conduct clinical trials of the Russian Coronavirus vaccine in India in September. As part of the cooperation, the RDIF will supply 100 million vaccine doses to Dr Reddy's upon regulatory approval in India.
"We are pleased to collaborate with the Indian regulators and in addition to Indian clinical trial data, we will provide safety and immunogenicity study from the Russian phase 3 clinical trial.
This data will further strengthen the clinical development of Sputnik V vaccine in India," Kirill Dmitriev, the RDIF CEO said, as quoted in a press release.
Russia registered the world's first Coronavirus vaccine, developed by the Gamaleya Institute, in August.
It is now completing phase 3 of clinical trials in Russia as per the WHO's protocols.
India is conducting trials for three COVID-19 vaccine candidates, including two domestically-developed. The Serum Institute of India, in turn, is completing phase 2 of clinical trials for the Oxford vaccine.
India cooperates in the vaccine development with five pharma companies, including AstraZeneca and Novavax.
UNI XC-GNK SHK1900